9 results on '"Parham Sendi"'
Search Results
2. An unusual clinical presentation of necrotizing fasciitis
- Author
-
Athanasios Papanikolaou, Radu Olariu, Jon Brugger, and Parham Sendi
- Subjects
Male ,Microbiology (medical) ,medicine.medical_specialty ,business.industry ,MEDLINE ,General Medicine ,Middle Aged ,Amoxicillin-Potassium Clavulanate Combination ,medicine.disease ,Dermatology ,Anti-Bacterial Agents ,Treatment Outcome ,Infectious Diseases ,570 Life sciences ,biology ,Humans ,Medicine ,Fasciitis, Necrotizing ,Presentation (obstetrics) ,610 Medicine & health ,business ,Fasciitis - Published
- 2020
3. Time kill assays for Streptococcus agalactiae and synergy testing
- Author
-
Parham Sendi and Corinne Ruppen
- Subjects
Streptococcus agalactiae ,medicine ,General Earth and Planetary Sciences ,Biology ,medicine.disease_cause ,General Environmental Science ,Microbiology - Published
- 2015
4. Pathogenesis of implant-associated infection: the role of the host
- Author
-
Parham Sendi and Werner Zimmerli
- Subjects
Prosthesis-Related Infections ,Biocompatibility ,Phagocytosis ,Immunology ,Biofilm ,Biocompatible Materials ,Inflammation ,Prostheses and Implants ,Biology ,Antimicrobial ,Bacterial Adhesion ,Immunity, Innate ,Microbiology ,Surface coating ,Neointima ,Host-Pathogen Interactions ,medicine ,Animals ,Humans ,Immunology and Allergy ,Implant ,medicine.symptom ,Prosthesis-Related Infection - Abstract
Implanted devices are mainly used to improve impaired function or to replace missing anatomic structures. They are made of synthetic material or devitalized biological structures. In contrast to vital transplants, they are not rejected by the body. However, the host reacts against these foreign bodies, a process which can be designated as biocompatibility. The interaction of the device with adjacent granulocytes and complement not only induces various degrees of inflammation but also impairs local microbial clearance. Foreign surfaces are a preferred target for bacterial adherence. While adhering bacteria are highly resistant to the bactericidal activity of phagocytes, they are also resistant to most antimicrobial agents. Certain bacteria may reside within host cells, and hence, evade host defense mechanisms by persisting intracellularly around implants. Nanotechnology minimizes clotting activation and bacterial adhesion by intravascular devices. Furthermore, surface coating with appropriate substances favorably influences biocompatibility as well as susceptibility to infection. In the future, "Microsystems Technology" deployed as intelligent device may decrease the risk of implant failure due to infection.
- Published
- 2011
5. Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care
- Author
-
Thomas Klimkait, Katarina Petrovic, A. Holbro, Henning Drechsler, Parham Sendi, Hans H. Hirsch, François Hamy, and Manuel Battegay
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Nevirapine ,Genotype ,Anti-HIV Agents ,Population ,HIV Infections ,Drug resistance ,Biology ,Ambulatory Care Facilities ,Indinavir ,Internal medicine ,Drug Resistance, Viral ,medicine ,Humans ,education ,Didanosine ,Aged ,education.field_of_study ,food and beverages ,Lamivudine ,Lopinavir ,General Medicine ,Middle Aged ,Viral Load ,Phenotype ,Infectious Diseases ,Immunology ,HIV-1 ,Female ,Viral load ,medicine.drug - Abstract
Data on genotypic and phenotypic resistance testing of HIV-1 in the routine clinical setting are lacking. In a retrospective single-center study, all patients (n = 102) for whom genotypic resistance typing (GRT) and phenotypic resistance typing (PRT) were performed during the calendar year 2002 were examined. GRT and PRT results were concordant for 79% of the drugs, being highest for nevirapine (92%) and lowest for didanosine (57%). Concordance of results for protease inhibitors was lowest for lopinavir (78%) and highest for indinavir (88%). Discordant results for lamivudine were observed in 16% of patients; 90% of these results corresponded to high-level resistance by PRT and susceptibility by GRT. Overall, HIV loads were lower and CD4+ cell counts higher after therapy following resistance testing, but a significant association with the number of active drugs as predicted by GRT or PRT could not be identified. In a subgroup of 43 patients with virological failure under antiretroviral therapy and sufficient follow-up data, HIV loads were significantly lower after 3 and 6 months. More patients with HIV loads
- Published
- 2005
6. The cost-effectiveness of different management strategies for Type I diabetes: a Swiss perspective
- Author
-
K. Neeser, A Brandt, C. Weiss, Parham Sendi, H. Wenzel, Giatgen A. Spinas, Andrew J. Palmer, and G. Singh
- Subjects
medicine.medical_specialty ,Pediatrics ,Cost effectiveness ,Cost-Benefit Analysis ,Endocrinology, Diabetes and Metabolism ,End stage renal disease ,Life Expectancy ,Diabetes management ,Diabetes mellitus ,Internal Medicine ,medicine ,Albuminuria ,Humans ,Insulin ,Mass Screening ,Diabetic Nephropathies ,Cumulative incidence ,Mass screening ,Diabetic Retinopathy ,Models, Statistical ,business.industry ,Incidence ,Diabetic retinopathy ,medicine.disease ,Markov Chains ,Surgery ,Diabetes Mellitus, Type 1 ,Life expectancy ,Kidney Failure, Chronic ,business ,Diabetic Angiopathies ,Switzerland - Abstract
Aims/hypothesis. A computer model was developed to determine the health outcomes and economic consequences of different combinations of diabetes interventions in newly diagnosed patients with Type I (insulin-dependent) diabetes in Switzerland.¶Methods. We modelled seven complications of diabetes: hypoglycaemia, ketoacidosis, acute myocardial infarction, stroke, lower extremity amputation, nephropathy, and retinopathy. Transition probabilities and costs were taken from published literature. The Swiss health insurance payer perspective was taken. Various combinations of diabetes management strategies, including intensive or conventional insulin therapy and screening and treatment strategies for renal and eye disease were defined. Life expectancy, cumulative incidences of complications, and mean expected total lifetime costs per patient were calculated under six different management strategies. Incremental cost-effectiveness ratios were calculated in terms of costs per life-year gained compared with conventional insulin therapy alone.¶Results. The addition of screening for microalbuminuria and retinopathy followed by appropriate treatment, if detected, were cost saving, with reduction in cumulative incidence of end stage renal disease and blindness respectively, and, in the case of microalbuminuria screening and treatment, an improvement in life expectancy. Intensive therapy improved life expectancy but increased total lifetime costs.¶Conclusion/interpretation. Optimal management of Type I diabetic patients, including secondary and tertiary prevention, leads to reduced complications and improved life expectancy, with the increased costs of prevention offset to varying degrees by cost savings due to complications avoided. [Diabetologia (2000) 43: 13–26]
- Published
- 2000
7. Broad-Range PCR in Selected Episodes of Prosthetic Joint Infection
- Author
-
Parham Sendi, M. Lüem, Peter E. Ochsner, Werner Zimmerli, F. H. R. De Man, and Peter Graber
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Infectious Diseases ,medicine ,Colony count ,Prosthetic joint infection ,General Medicine ,Biology ,Surgery - Published
- 2009
8. Rare AIDS-Defining Diseases in the Swiss HIV Cohort Study
- Author
-
Dominik Pfluger, Manuel Battegay, Heiner C. Bucher, Jürgen Drewe, Parham Sendi, Gyr N, Reto Nüesch, Werner Zimmerli, and B. Burckhardt
- Subjects
Adult ,Male ,Microbiology (medical) ,Pathology ,medicine.medical_specialty ,AIDS-Related Opportunistic Infections ,Isosporiasis ,Disseminated coccidioidomycosis ,Disease ,Meningitis, Cryptococcal ,Cohort Studies ,Prevalence ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Demography ,Lymphoma, AIDS-Related ,Mycobacterium kansasii ,Acquired Immunodeficiency Syndrome ,biology ,Brain Neoplasms ,business.industry ,Progressive multifocal leukoencephalopathy ,Leukoencephalopathy, Progressive Multifocal ,Herpes Simplex ,Cryptococcosis ,General Medicine ,medicine.disease ,biology.organism_classification ,Dermatology ,CD4 Lymphocyte Count ,Infectious Diseases ,Female ,business ,Switzerland - Abstract
The objective of this study was to investigate the spectrum and frequency of rare AIDS-defining diseases in the Swiss HIV Cohort Study. AIDS-defining diseases contributing less than 1% to the absolute number of all recorded AIDS-defining diseases in at least one of five periods (1988-1990, 1991-1992, 1993-1994, 1995-1996, 1997) were defined as being rare. A total of 9110 HIV-infected subjects were included in this study. Over the entire 9-year period, the following rare diseases were diagnosed: progressive multifocal leukoencephalopathy (n = 138), disseminated cryptococcosis (n = 67), visceral herpes simplex disease (n = 66), primary cerebral lymphoma (n = 65), indeterminate cerebral lesion (n = 50), cryptococcal meningitis (n = 34), Mycobacterium kansasii disease (n = 32), recurrent Salmonella septicemia (n = 22), intestinal isosporiasis (n = 21), candidiasis of the trachea, bronchi and lungs (n = 19), toxoplasma retinitis (n = 16), disseminated toxoplasmosis (n = 8), invasive cervical carcinoma (n = 8), extrapulmonary Pneumocystis disease (n = 5), disseminated histoplasmosis (n = 1) and disseminated coccidioidomycosis (n = 1). Rare diseases accounted for 7.3% of all AIDS-defining diseases over the entire 9-year period. Physicians should be aware of the likelihood of a broad spectrum of AIDS-defining diseases in HIV-infected patients.
- Published
- 1999
9. LL-37 at the local site of streptococcal skin and soft-tissue infections
- Author
-
Malak Kotb, Parham Sendi, Per Åkesson, Adam Linder, Pontus Thulin, Linda Johansson, Anna Norrby-Teglund, Donald E. Low, Bertil Christensson, Birgitta Agerberth, and Erika Hertzén
- Subjects
medicine.medical_specialty ,business.industry ,Poster Presentation ,medicine ,Soft tissue ,Critical Care and Intensive Care Medicine ,Bioinformatics ,business ,Dermatology - Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.